Circulating miRNA Panel for Early Pancreatic Cancer Detection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for detecting pancreatic cancer are inadequate in sensitivity and specificity, particularly in early stages, and often require invasive procedures, leading to high physical and economic burdens on patients.

Innovation Solution

An analysis method involving the quantification of specific microRNAs (miRNAs) such as hsa-miR-205-5p, hsa-miR-223-5p, hsa-miR-29c-3p, hsa-miR-324-3p, hsa-miR-34a-5p, and hsa-miR-885-5p, combined with a determination algorithm, to determine the presence or absence of pancreatic cancer using serum or plasma samples, reducing invasiveness and improving diagnostic accuracy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If current methods for detecting pancreatic cancer are used, then detection can be performed, but sensitivity and specificity are insufficient particularly in early stages

Engineering Contradiction:

Improvedetection accuracyVSAvoidsensitivity and specificity

Core Design Contradiction:

Measurement precisionVSReliability

Solution Approach 1:

The patent segments the detection task by identifying and measuring multiple specific miRNA molecules (hsa-miR-205-5p, hsa-miR-223-5p, hsa-miR-29c-3p, hsa-miR-324-3p, hsa-miR-34a-5p, and hsa-miR-885-5p) rather than using a single marker. This segmentation of the detection target into multiple specific biomolecules enables more precise and reliable detection of pancreatic cancer, particularly in early stages

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent changes the detection parameters by focusing on specific miRNA expression levels and ratios rather than traditional markers. By quantifying the expression levels of six specific miRNAs and calculating their ratios, the method achieves improved sensitivity and specificity for detecting pancreatic cancer at early stages

Inventive Principle:

Principle #35Parameter changes

2Reliability

If invasive procedures are used for detection, then diagnostic information can be obtained, but patient burden increases physically and economically

Engineering Contradiction:

Improvediagnostic informationVSAvoidpatient burden

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent extracts diagnostic information from easily accessible biological samples such as serum or plasma rather than requiring invasive tissue biopsies. By detecting miRNA expression profiles in these liquid biopsies, the method obtains reliable diagnostic information while significantly reducing patient burden and procedural invasiveness

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent uses miRNAs in serum or plasma as intermediary biomarkers that reflect the presence of pancreatic cancer without requiring direct sampling of tumor tissue. These circulating miRNAs serve as mediators that carry diagnostic information from the tumor site to accessible body fluids, enabling non-invasive detection

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20250376735A1Analysis method, marker, and kit

Publication Date: 2025.12.11 KK TOSHIBA

AI summary

According to one embodiment, an analysis method for determining a presence or absence of pancreatic cancer in a test subject, comprising quantifying corrective miRNA and target miRNAs in a sample derived from the test subject, wherein the target miRNAs are three or more selected from a group consisting of hsa-miR-205-5p, hsa-miR-223-5p, hsa-miR-29c-3p, hsa-miR-324-3p, hsa-miR-34a-5p, hsa-miR-483-5p and hsa-miR-885-5p.